• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IDEX Reports First Quarter Results

    4/29/26 7:00:00 AM ET
    $IEX
    Fluid Controls
    Industrials
    Get the next $IEX alert in real time by email

    Highlights

    (All comparisons are against the prior year period unless otherwise noted)

    • Sales of $887 million increased 9% on a reported basis and 5% organically
    • Reported diluted EPS of $1.61 increased 28% and adjusted diluted EPS of $2.00 increased 14%
    • Record orders of $988 million increased 13% on a reported basis and increased 10% organically
    • Returned capital to shareholders via $76 million of share repurchases and $53 million of dividends
    • Raising full year 2026 organic growth and adjusted EPS guidance ranges

     

    IDEX Corporation (NYSE:IEX) today announced its financial results for the three-month period ended March 31, 2026.

    "We delivered a strong first quarter, with results ahead of our expectations led by continued momentum in our growth platforms within our Health & Science Technologies segment," said Eric D. Ashleman, IDEX Corporation Chief Executive Officer and President.

    "Our first quarter results demonstrate that our strategy is working, with strong execution across the portfolio and increasing traction in the markets where we are choosing to compete. The application of 8020 continues to sharpen our priorities and reallocate resources toward opportunities with stronger growth and margin profiles."

    "Based on this momentum, we are raising our full-year guidance and are encouraged by how our strategies are translating into higher-quality growth. We remain focused on disciplined execution as we continue to build long-term value at IDEX."

    Outlook(1)

    • Full year organic sales projected to increase 3% to 4% over the prior year, up from previous guidance of 1% to 2%
    • Full year adjusted diluted EPS of $8.35 to $8.55, up from previous guidance of $8.15 to $8.35
    • Second quarter 2026 organic sales projected to increase 3% to 4% from the prior year period
    • Second quarter 2026 adjusted diluted EPS of $2.07 to $2.12

    (1) The Company does not reconcile its forward-looking non-GAAP measures to the most directly comparable U.S. GAAP financial measure because the timing and magnitude of certain items, including future foreign exchange impacts, acquisitions, divestitures, restructuring costs, impairments, tax impacts, and other special items, cannot be reasonably estimated at this time without unreasonable effort. The unavailable information could have a significant impact on GAAP results.

    Consolidated Financial Results

     

    Three Months Ended March 31,

    (Dollars in millions, except per share amounts)

    2026

     

    2025

     

    Increase (Decrease)

    U.S. GAAP Results

     

     

     

     

     

    Orders

    $

    988.3

     

    $

    871.9

     

    $

    116.4

    Change in reported orders

     

     

     

     

     

    13%

    Net sales

     

    886.9

     

     

    814.3

     

     

    72.6

    Change in reported net sales

     

     

     

     

     

    9%

    Gross profit

     

    398.1

     

     

    368.9

     

     

    29.2

    Gross margin

     

    44.9%

     

     

    45.3%

     

    (40) bps

    Net income attributable to IDEX

     

    120.0

     

     

    95.5

     

     

    24.5

    Net income margin

     

    13.5%

     

     

    11.7%

     

    180 bps

    Diluted EPS attributable to IDEX

     

    1.61

     

     

    1.26

     

     

    0.35

    Cash flows from operating activities

     

    103.7

     

     

    105.7

     

     

    (2.0)

    Operating cash flow as a percent of net income

     

    86%

     

     

    111%

     

     

    NM

    Non-GAAP Results*

     

     

     

     

     

    Change in organic orders

     

     

     

     

     

    10%

    Change in organic sales

     

     

     

     

     

    5%

    Adjusted gross profit(1)

     

    398.1

     

     

    368.9

     

     

    29.2

    Adjusted gross margin(1)

     

    44.9%

     

     

    45.3%

     

    (40) bps

    Adjusted net income attributable to IDEX

     

    148.6

     

     

    133.0

     

     

    15.6

    Adjusted EBITDA

     

    230.4

     

     

    208.0

     

     

    22.4

    Adjusted EBITDA margin

     

    26.0%

     

     

    25.5%

     

    50 bps

    Adjusted diluted EPS attributable to IDEX

     

    2.00

     

     

    1.75

     

     

    0.25

    Free cash flow

     

    86.0

     

     

    91.4

     

     

    (5.4)

    Free cash flow conversion

     

    58 %

     

     

    69 %

     

     

    NM

    NM – Not Meaningful

    *Each of these items below are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled "Non-GAAP Measures of Financial Performance" and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release.

     

    (1) Adjusted gross profit is calculated as Gross profit plus fair value inventory step-up charges. Adjusted gross margin is calculated as Adjusted gross profit divided by Net sales. There were no fair value inventory step-up charges recorded during the three months ended March 31, 2026 or March 31, 2025.

    • Net sales increased as a result of increased organic sales, as well as favorable impacts from foreign currency and contributions from acquisitions. The increase in organic sales was driven by higher volumes in our Health & Science Technologies ("HST") segment, which were slightly offset by lower volumes in our Fire & Safety/Diversified Products ("FSDP") and Fluid & Metering Technologies ("FMT") segments. The increase also reflects positive price across our businesses.
    • Gross margin decreased due to unfavorable mix and pressured price/cost, partially offset by net productivity improvements and volume leverage.
    • Both Diluted EPS and Adjusted diluted EPS increased, primarily due to improved operational results discussed above. GAAP Diluted EPS also reflects lower restructuring and asset impairment expense, which was excluded from Adjusted diluted EPS.
    • Cash flows from operating activities and free cash flow were both slightly down compared to the prior year period. Higher earnings were offset by the timing of customer payments. Free cash flow also reflects higher capital expenditures during the current year period.

    Segment Financial Results

     

    Three Months Ended March 31,(1)

    (Dollars in millions)

    2026

     

    2025

     

    Increase (Decrease)

    Health & Science Technologies

     

     

     

     

     

    Net sales

    $

    398.4

     

    $

    341.5

     

    $

    56.9

    Change in reported net sales

     

     

     

     

     

    17%

    Change in organic sales*

     

     

     

     

     

    11%

    Adjusted EBITDA(2)

     

    106.0

     

     

    87.4

     

     

    18.6

    Adjusted EBITDA margin

     

    26.6%

     

     

    25.6%

     

    100 bps

    Fluid & Metering Technologies

     

     

     

     

     

    Net sales

    $

    301.5

     

    $

    290.5

     

    $

    11.0

    Change in reported net sales

     

     

     

     

     

    4%

    Change in organic sales*

     

     

     

     

     

    2%

    Adjusted EBITDA(2)

     

    98.7

     

     

    95.3

     

     

    3.4

    Adjusted EBITDA margin

     

    32.7%

     

     

    32.8%

     

    (10) bps

    Fire & Safety/Diversified Products

     

     

     

     

     

    Net sales

    $

    188.3

     

    $

    184.3

     

    $

    4.0

    Change in reported net sales

     

     

     

     

     

    2%

    Change in organic sales*

     

     

     

     

     

    (1%)

    Adjusted EBITDA(2)

     

    55.8

     

     

    54.2

     

     

    1.6

    Adjusted EBITDA margin

     

    29.7%

     

     

    29.4%

     

    30 bps

    *These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled "Non-GAAP Measures of Financial Performance" and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release.

    (1) Three month data includes the results of the acquisition of Micro-LAM, Inc. ("Micro-LAM") (July 2025) in the HST segment.

    (2) Segment Adjusted EBITDA excludes unallocated corporate costs which are included in Corporate and other.

    Health & Science Technologies Segment

    • Net sales for the first quarter 2026 increased 17%. Organic sales increased 11% due to higher volumes primarily due to AI-driven demand for data center power and semiconductor markets, as well as strength in space and defense, partially offset by lower volumes in our life sciences businesses. Net sales also reflect positive price across the segment.
    • Adjusted EBITDA margin for the first quarter 2026 increased primarily due to volume leverage and favorable price/cost, partially offset by unfavorable mix and acquisitions.

    Fluid & Metering Technologies Segment

    • Net sales for the first quarter 2026 increased 4%. Organic sales increased 2% primarily driven by positive price. Higher volumes in our businesses serving municipal water, semiconductor and mining markets were more than offset by lower volumes in our chemical and general industrial businesses.
    • Adjusted EBITDA margin for the first quarter 2026 decreased primarily due to unfavorable mix and volume deleverage, mostly mitigated by net productivity improvements.

    Fire & Safety/Diversified Products Segment

    • Net sales for the first quarter 2026 increased 2%. Organic sales decreased 1%. Higher volumes in our Fire & Safety businesses and positive price were more than offset by lower volumes within our Dispensing businesses driven by timing of projects.
    • Adjusted EBITDA margin for the first quarter 2026 increased primarily due to net productivity improvements, partially offset by unfavorable mix and volume deleverage.

    Corporate Costs

    Corporate costs included in consolidated Adjusted EBITDA were $30.1 million during the first quarter 2026, up slightly from $28.9 million during the same prior year period driven by higher employee-related costs.

    Conference Call

    IDEX will host its first quarter earnings conference call on Wednesday, April 29, 2026 at 8:00 a.m. CT. The call will be an audio webcast and accessible on the Company's Investor Relations site at https://investors.idexcorp.com. Associated earnings presentation materials will be available on the Company's website prior to the call.

    Interested parties can access the conference by dialing 888.596.4144 and using confirmation code #2518354. Please connect five minutes prior to the start of the conference call.

    A replay of the earnings call and associated earnings presentation materials will be available on the Company's website after the call.

    Forward-Looking Statements

    This news release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company's second quarter 2026 and full year 2026 outlook including expected organic sales and expected adjusted earnings per share and the assumptions underlying these expectations, capital return strategy, anticipated future acquisition behavior and the anticipated benefits and performance of the Company's recent or future acquisitions, resource and capital deployment and focus and organic and inorganic growth, the Company's ability to adapt to macroeconomic challenges, anticipated impacts of tariffs and global trade policies and changes in law, anticipated trends in end markets, including expectations regarding future order volumes and order patterns, anticipated growth initiatives and expansions and execution of those growth initiatives and are indicated by words or phrases such as "anticipates," "estimates," "plans," "guidance," "expects," "projects," "forecasts," "should," "could," "will," "likely to be," "management believes," "the Company believes," "the Company intends" and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release.

    The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries; the impact of severe weather events, natural disasters and public health threats; economic and political consequences resulting from terrorist attacks, wars and global conflicts; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; cybersecurity incidents; the continued growth of artificial intelligence ("AI") and any related changes to demand in AI-driven markets served by the Company's customers; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in countries in which the Company operates; developments with respect to trade policy and existing, new or increased tariffs or other similar measures; changes to applicable laws and regulations, including tax laws; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters.

    Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the "Risk Factors" section included in the Company's most recent annual report on Form 10-K and the Company's subsequent quarterly reports filed with the United States Securities and Exchange Commission ("SEC") and the other risks discussed in the Company's filings with the SEC. The forward-looking statements included here are only made as of the date of this news release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

    About IDEX

    IDEX Corporation (NYSE:IEX), a global engineered products company, is comprised of three primary business segments – Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety/Diversified Products. Thousands of IDEX employees around the world design and manufacture highly engineered components and applied solutions that are vital to the advances of modern life and help IDEX live its purpose – Trusted Solutions, Improving Lives™. From satellite communications to water systems, from medical diagnostic components to emergency rescue tools and more, we collaborate with customers in the most critical industries to develop solutions that make the world better today and into the future. Founded in 1988, IDEX now includes more than 50 dynamic businesses around the world and manufacturing operations in more than 20 countries.

    For further information on IDEX Corporation and its business units, visit the Company's website at www.idexcorp.com.

    (Financial reports follow)

    IDEX CORPORATION

    Condensed Consolidated Statements of Income

    (in millions, except per share amounts)

    (unaudited)

     

     

    Three Months Ended March 31,

     

    2026

     

    2025

    Net sales

    $

    886.9

     

     

    $

    814.3

    Cost of sales

     

    488.8

     

     

     

    445.4

    Gross profit

     

    398.1

     

     

     

    368.9

    Selling, general and administrative expenses

     

    218.3

     

     

     

    209.4

    Restructuring expenses and asset impairments

     

    7.4

     

     

     

    17.5

    Operating income

     

    172.4

     

     

     

    142.0

    Other (income) expense – net

     

    (0.6

    )

     

     

    1.4

    Interest expense – net

     

    16.0

     

     

     

    16.1

    Income before income taxes

     

    157.0

     

     

     

    124.5

    Provision for income taxes

     

    37.1

     

     

     

    29.1

    Net income

     

    119.9

     

     

     

    95.4

    Net loss attributable to noncontrolling interest

     

    0.1

     

     

     

    0.1

    Net income attributable to IDEX

    $

    120.0

     

     

    $

    95.5

     

     

     

     

    Earnings per Common Share:

     

     

     

    Basic earnings per common share attributable to IDEX

    $

    1.61

     

     

    $

    1.26

    Diluted earnings per common share attributable to IDEX

    $

    1.61

     

     

    $

    1.26

     

     

     

     

    Share Data:

     

     

     

    Basic weighted average common shares outstanding

     

    74.3

     

     

     

    75.7

    Diluted weighted average common shares outstanding

     

    74.4

     

     

     

    75.8

    IDEX CORPORATION

    Condensed Consolidated Balance Sheets

    (in millions)

    (unaudited)

     

     

    March 31, 2026

     

    December 31, 2025

    Assets

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    586.2

     

     

    $

    580.0

     

    Receivables – net

     

    553.0

     

     

     

    521.7

     

    Inventories – net

     

    501.0

     

     

     

    479.4

     

    Other current assets

     

    76.5

     

     

     

    62.1

     

    Total current assets

     

    1,716.7

     

     

     

    1,643.2

     

    Property, plant and equipment – net

     

    462.3

     

     

     

    468.0

     

    Goodwill

     

    3,390.2

     

     

     

    3,414.5

     

    Intangible assets - net

     

    1,200.2

     

     

     

    1,247.4

     

    Other noncurrent assets

     

    149.2

     

     

     

    153.9

     

    Total assets

    $

    6,918.6

     

     

    $

    6,927.0

     

     

     

     

     

    Liabilities and equity

     

     

     

    Current liabilities

     

     

     

    Trade accounts payable

    $

    224.8

     

     

    $

    224.7

     

    Accrued expenses

     

    280.6

     

     

     

    297.0

     

    Current portion of long-term borrowings

     

    0.5

     

     

     

    0.7

     

    Dividends payable

     

    0.1

     

     

     

    53.0

     

    Total current liabilities

     

    506.0

     

     

     

    575.4

     

    Long-term borrowings – net

     

    1,871.8

     

     

     

    1,820.1

     

    Deferred income taxes

     

    299.5

     

     

     

    303.0

     

    Other noncurrent liabilities

     

    192.9

     

     

     

    202.3

     

    Total liabilities

     

    2,870.2

     

     

     

    2,900.8

     

    Shareholders' equity

     

     

     

    Preferred stock

     

    —

     

     

     

    —

     

    Common stock

     

    0.9

     

     

     

    0.9

     

    Treasury stock

     

    (1,453.6

    )

     

     

    (1,423.2

    )

    Additional paid-in capital

     

    868.5

     

     

     

    892.1

     

    Retained earnings

     

    4,620.1

     

     

     

    4,500.1

     

    Accumulated other comprehensive income

     

    13.9

     

     

     

    57.6

     

    Total shareholders' equity

     

    4,049.8

     

     

     

    4,027.5

     

    Noncontrolling interest

     

    (1.4

    )

     

     

    (1.3

    )

    Total equity

     

    4,048.4

     

     

     

    4,026.2

     

    Total liabilities and equity

    $

    6,918.6

     

     

    $

    6,927.0

     

    IDEX CORPORATION

    Condensed Consolidated Statements of Cash Flows

    (in millions)

    (unaudited)

     

     

    Three Months Ended March 31,

     

    2026

     

    2025

    Cash flows from operating activities

     

     

     

    Net income

    $

    119.9

     

     

    $

    95.4

     

    Adjustments to reconcile net income to net cash flows provided by operating activities:

     

     

     

    Asset impairments

     

    4.8

     

     

     

    —

     

    Depreciation

     

    19.9

     

     

     

    18.4

     

    Amortization of intangible assets

     

    33.8

     

     

     

    31.5

     

    Share-based compensation expense

     

    15.8

     

     

     

    13.6

     

    Deferred income taxes

     

    (0.6

    )

     

     

    0.9

     

    Changes in (net of the effect from acquisitions/divestitures and foreign currency translation):

     

     

     

    Receivables – net

     

    (35.4

    )

     

     

    (12.3

    )

    Inventories – net

     

    (25.5

    )

     

     

    (34.9

    )

    Other current assets

     

    (15.1

    )

     

     

    (7.0

    )

    Trade accounts payable

     

    0.6

     

     

     

    9.6

     

    Deferred revenue

     

    4.2

     

     

     

    8.8

     

    Accrued expenses

     

    (18.8

    )

     

     

    (17.9

    )

    Other – net

     

    0.1

     

     

     

    (0.4

    )

    Net cash flows provided by operating activities

     

    103.7

     

     

     

    105.7

     

    Cash flows from investing activities

     

     

     

    Capital expenditures

     

    (17.7

    )

     

     

    (14.3

    )

    Acquisition of business, net of cash acquired

     

    —

     

     

     

    4.2

     

    Other – net

     

    (2.7

    )

     

     

    0.1

     

    Net cash flows used in investing activities

     

    (20.4

    )

     

     

    (10.0

    )

    Cash flows from financing activities

     

     

     

    Borrowings under revolving credit facilities

     

    100.0

     

     

     

    —

     

    Payments under revolving credit facilities

     

    (45.3

    )

     

     

    (30.2

    )

    Cash dividends paid to shareholders

     

    (52.8

    )

     

     

    (52.4

    )

    Proceeds (payments) from share issuances, net of shares withheld for taxes

     

    5.8

     

     

     

    (0.5

    )

    Repurchases of common stock

     

    (76.3

    )

     

     

    (50.0

    )

    Other – net

     

    (0.2

    )

     

     

    (0.2

    )

    Net cash flows used in financing activities

     

    (68.8

    )

     

     

    (133.3

    )

    Effect of exchange rate changes on cash and cash equivalents

     

    (8.6

    )

     

     

    10.9

     

    Net increase (decrease) in cash and cash equivalents and restricted cash

     

    5.9

     

     

     

    (26.7

    )

    Cash and cash equivalents and restricted cash at beginning of year(1)

     

    585.9

     

     

     

    638.9

     

    Cash and cash equivalents and restricted cash at end of period(1)

    $

    591.8

     

     

    $

    612.2

     

    (1)

     

    The Company has restricted cash related to certain letters of credit and is required to keep these balances in separate accounts for the duration of the letter of credit agreements. The underlying letters of credit expire between June 2026 and July 2027. The Company also has restricted cash related to funds held in escrow for the payment of certain merger consideration in connection with the acquisition of Micro-LAM. These payments are expected to be paid between July 2026 and January 2028. Restricted cash is included in the Condensed Consolidated Balance Sheets as follows:

     

    Restricted Cash

     

    March 31, 2026

     

    December 31, 2025

     

    March 31, 2025

     

    December 31, 2024

    Other current assets

    $

    2.7

     

    $

    3.0

     

    $

    16.5

     

    $

    18.1

    Other noncurrent assets

     

    2.9

     

     

    2.9

     

     

    1.6

     

     

    —

    Total

    $

    5.6

     

    $

    5.9

     

    $

    18.1

     

    $

    18.1

    IDEX CORPORATION

    Company and Segment Financial Information

    (in millions)

    (unaudited)

     

     

    Three Months Ended March 31,

     

    2026

     

    2025

    Net sales

     

     

     

    Health & Science Technologies

    $

    398.4

     

     

    $

    341.5

     

    Fluid & Metering Technologies

     

    301.5

     

     

     

    290.5

     

    Fire & Safety/Diversified Products

     

    188.3

     

     

     

    184.3

     

    Eliminations

     

    (1.3

    )

     

     

    (2.0

    )

    Total IDEX

    $

    886.9

     

     

    $

    814.3

     

    Depreciation

     

     

     

    Health & Science Technologies

    $

    12.5

     

     

    $

    11.7

     

    Fluid & Metering Technologies

     

    4.9

     

     

     

    4.4

     

    Fire & Safety/Diversified Products

     

    2.4

     

     

     

    2.2

     

    Corporate Office

     

    0.1

     

     

     

    0.1

     

    Total IDEX

    $

    19.9

     

     

    $

    18.4

     

    Amortization of intangible assets

     

     

     

    Health & Science Technologies

    $

    27.1

     

     

    $

    24.6

     

    Fluid & Metering Technologies

     

    5.4

     

     

     

    5.3

     

    Fire & Safety/Diversified Products

     

    1.3

     

     

     

    1.6

     

    Total IDEX

    $

    33.8

     

     

    $

    31.5

     

    Restructuring expenses and asset impairments

     

     

     

    Health & Science Technologies

    $

    1.1

     

     

    $

    11.4

     

    Fluid & Metering Technologies

     

    5.1

     

     

     

    4.2

     

    Fire & Safety/Diversified Products

     

    0.3

     

     

     

    1.6

     

    Corporate Office

     

    0.9

     

     

     

    0.3

     

    Total IDEX

    $

    7.4

     

     

    $

    17.5

     

    Non-GAAP Measures of Financial Performance

    The Company prepares its public financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The Company supplements certain U.S. GAAP financial performance metrics with non-GAAP financial performance metrics. Management believes these non-GAAP financial performance metrics provide investors with greater insight, transparency and a more comprehensive understanding of the financial information used by management in its financial and operational decision making because certain of these adjusted metrics exclude items not reflective of ongoing operations, as identified in the reconciliations below. Reconciliations of non-GAAP financial performance metrics to their most directly comparable U.S. GAAP financial performance metrics are defined and presented below and should not be considered a substitute for, nor superior to, the financial data prepared in accordance with U.S. GAAP. Due to rounding, numbers presented throughout this and other documents may not add up or recalculate precisely.

    All table footnotes can be found at the end of this Non-GAAP Measures section. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below.

    • Organic orders and organic sales are calculated as orders and Net sales excluding amounts from acquired or divested businesses during the first twelve months of ownership or prior to divestiture and excluding the impact of foreign currency translation.
    • Adjusted gross profit is calculated as Gross profit plus fair value inventory step-up charges. There were no fair value inventory step-up charges recorded during the three months ended March 31, 2026 or March 31, 2025.
    • Adjusted gross margin is calculated as Adjusted gross profit divided by Net sales. There were no fair value inventory step-up charges recorded during the three months ended March 31, 2026 or March 31, 2025.
    • Adjusted net income attributable to IDEX is calculated as Net income attributable to IDEX plus Restructuring expenses and asset impairments, plus acquisition-related intangible asset amortization, less gain on legal settlement, all net of the statutory tax expense or benefit.
    • Adjusted diluted EPS attributable to IDEX is calculated as adjusted net income attributable to IDEX divided by the diluted weighted average shares outstanding.
    • Consolidated Adjusted EBITDA is calculated as consolidated earnings before interest expense - net, income taxes, depreciation and amortization, or consolidated EBITDA, plus Restructuring expenses and asset impairments, less gain on legal settlement.
    • Consolidated Adjusted EBITDA margin is calculated as Consolidated Adjusted EBITDA divided by Net sales.
    • Free cash flow is calculated as cash flows from operating activities less capital expenditures. Free cash flow conversion is calculated as free cash flow divided by adjusted net income attributable to IDEX.

    Table 1: Reconciliations of the Change in Net Sales to Organic Sales

     

     

     

     

     

     

     

     

     

    HST

     

    FMT

     

    FSDP

     

    IDEX

     

    Three Months Ended March 31, 2026

    Change in net sales

    17

    %

     

    4

    %

     

    2

    %

     

    9

    %

    Less:

     

     

     

     

     

     

     

    Net impact from acquisitions/divestitures(1)

    3

    %

     

    —

    %

     

    —

    %

     

    1

    %

    Impact from foreign currency(2)

    3

    %

     

    2

    %

     

    3

    %

     

    3

    %

    Change in organic sales

    11

    %

     

    2

    %

     

    (1

    %)

     

    5

    %

    Table 2: Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts)

     

     

     

     

     

     

     

    Three Months Ended March 31,

     

     

    2026

     

    2025

    Reported net income attributable to IDEX

     

    $

    120.0

     

     

    $

    95.5

     

    Restructuring expenses and asset impairments

     

     

    7.4

     

     

     

    17.5

     

    Tax impact on restructuring expenses and asset impairments

     

     

    (1.7

    )

     

     

    (4.1

    )

    Gain on legal settlement(3)

     

     

    (3.7

    )

     

     

    —

     

    Tax impact on gain of legal settlement

     

     

    0.8

     

     

     

    —

     

    Acquisition-related intangible asset amortization

     

     

    33.8

     

     

     

    31.5

     

    Tax impact on acquisition-related intangible asset amortization

     

     

    (8.0

    )

     

     

    (7.4

    )

    Adjusted net income attributable to IDEX

     

    $

    148.6

     

     

    $

    133.0

     

     

     

     

     

     

    Reported diluted EPS attributable to IDEX

     

    $

    1.61

     

     

    $

    1.26

     

    Restructuring expenses and asset impairments

     

     

    0.10

     

     

     

    0.23

     

    Tax impact on restructuring expenses and asset impairments

     

     

    (0.02

    )

     

     

    (0.05

    )

    Gain on legal settlement(3)

     

     

    (0.05

    )

     

     

    —

     

    Tax impact on gain of legal settlement

     

     

    0.01

     

     

     

    —

     

    Acquisition-related intangible asset amortization

     

     

    0.46

     

     

     

    0.41

     

    Tax impact on acquisition-related intangible asset amortization

     

     

    (0.11

    )

     

     

    (0.10

    )

    Adjusted diluted EPS attributable to IDEX

     

    $

    2.00

     

     

    $

    1.75

     

     

     

     

     

     

    Diluted weighted average shares outstanding

     

     

    74.4

     

     

     

    75.8

     

    Table 3: Reconciliations of Net Income to Adjusted EBITDA (dollars in millions)

     

     

    Three Months Ended March 31,

     

    2026

     

    2025

    Reported net income

    $

    119.9

     

     

    $

    95.4

     

    Provision for income taxes

     

    37.1

     

     

     

    29.1

     

    Interest expense - net

     

    16.0

     

     

     

    16.1

     

    Depreciation

     

    19.9

     

     

     

    18.4

     

    Amortization

     

    33.8

     

     

     

    31.5

     

    Restructuring expenses and asset impairments

     

    7.4

     

     

     

    17.5

     

    Gain on legal settlement(3)

     

    (3.7

    )

     

     

    —

     

    Adjusted EBITDA

    $

    230.4

     

     

    $

    208.0

     

     

     

     

     

    Adjusted EBITDA Components

     

     

     

    HST

    $

    106.0

     

     

    $

    87.4

     

    FMT

     

    98.7

     

     

     

    95.3

     

    FSDP

     

    55.8

     

     

     

    54.2

     

    Corporate and other

     

    (30.1

    )

     

     

    (28.9

    )

    Total Adjusted EBITDA

    $

    230.4

     

     

    $

    208.0

     

     

     

     

     

    Net sales

    $

    886.9

     

     

    $

    814.3

     

     

     

     

     

    Net income margin

     

    13.5

    %

     

     

    11.7

    %

    Adjusted EBITDA margin

     

    26.0

    %

     

     

    25.5

    %

    Table 4: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (dollars in millions)

     

     

    Three Months Ended March 31,

     

    2026

     

    2025

    Cash flows from operating activities

    $

    103.7

     

     

    $

    105.7

     

    Less: Capital expenditures

     

    17.7

     

     

     

    14.3

     

    Free cash flow

    $

    86.0

     

     

    $

    91.4

     

     

     

     

     

    Reported net income attributable to IDEX

    $

    120.0

     

     

    $

    95.5

     

    Adjusted net income attributable to IDEX

     

    148.6

     

     

     

    133.0

     

     

     

     

     

    Operating cash flow as a percent of net income

     

    86

    %

     

     

    111

    %

    Free cash flow conversion

     

    58

    %

     

     

    69

    %

    (1) Represents the sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture.

     

    (2) The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales, and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period.

     

    (3) Gain on legal settlement represents settlement funds received in excess of legal costs incurred related to a patent infringement lawsuit within the FMT segment.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260429987808/en/

    Investor Contact:

    Jim Giannakouros, CFA

    Vice President, Investor Relations

    (847) 313-9506

    Get the next $IEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IEX

    DatePrice TargetRatingAnalyst
    3/27/2026$214.00Market Perform
    BMO Capital Markets
    2/6/2026$240.00Hold → Buy
    Argus
    8/14/2024Buy → Hold
    Argus
    2/8/2024$215.00 → $265.00Hold → Buy
    Stifel
    10/5/2023$200.00Neutral
    Exane BNP Paribas
    7/18/2022$229.00 → $188.00Buy → Hold
    Stifel
    7/14/2022$215.00Perform → Outperform
    Oppenheimer
    3/9/2022Market Perform → Outperform
    Cowen & Co.
    More analyst ratings

    $IEX
    SEC Filings

    View All

    SEC Form SD filed by IDEX Corporation

    SD - IDEX CORP /DE/ (0000832101) (Filer)

    5/28/26 4:24:25 PM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - IDEX CORP /DE/ (0000832101) (Filer)

    5/8/26 1:36:45 PM ET
    $IEX
    Fluid Controls
    Industrials

    SEC Form 10-Q filed by IDEX Corporation

    10-Q - IDEX CORP /DE/ (0000832101) (Filer)

    4/29/26 4:33:00 PM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Christenson Carl R bought $101,647 worth of shares (600 units at $169.41), increasing direct ownership by 10% to 6,351 units (SEC Form 4)

    4 - IDEX CORP /DE/ (0000832101) (Issuer)

    11/7/25 4:50:06 PM ET
    $IEX
    Fluid Controls
    Industrials

    Director Helmkamp Katrina L bought $399,026 worth of shares (2,500 units at $159.61), increasing direct ownership by 23% to 13,200 units (SEC Form 4)

    4 - IDEX CORP /DE/ (0000832101) (Issuer)

    8/11/25 4:22:26 PM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets initiated coverage on IDEX Corp with a new price target

    BMO Capital Markets initiated coverage of IDEX Corp with a rating of Market Perform and set a new price target of $214.00

    3/27/26 8:50:54 AM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corp upgraded by Argus with a new price target

    Argus upgraded IDEX Corp from Hold to Buy and set a new price target of $240.00

    2/6/26 7:51:56 AM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corp downgraded by Argus

    Argus downgraded IDEX Corp from Buy to Hold

    8/14/24 7:53:05 AM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IDEX Corporation Declares Regular Quarterly Cash Dividend

    IDEX CORPORATION (NYSE:IEX) today announced that its Board of Directors has approved a regular quarterly cash dividend of $0.73 per common share. This dividend will be paid June 5, 2026 to shareholders of record as of May 22, 2026. This dividend represents the company's 126th consecutive regular quarterly cash dividend payment. About IDEX IDEX Corporation (NYSE:IEX), a global engineered products company, is comprised of three primary business segments – Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety / Diversified Products. Thousands of IDEX employees around the world design and manufacture highly engineered components and applied solutions that are vital

    5/6/26 1:51:00 PM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Reports First Quarter Results

    Highlights (All comparisons are against the prior year period unless otherwise noted) Sales of $887 million increased 9% on a reported basis and 5% organically Reported diluted EPS of $1.61 increased 28% and adjusted diluted EPS of $2.00 increased 14% Record orders of $988 million increased 13% on a reported basis and increased 10% organically Returned capital to shareholders via $76 million of share repurchases and $53 million of dividends Raising full year 2026 organic growth and adjusted EPS guidance ranges   IDEX Corporation (NYSE:IEX) today announced its financial results for the three-month period ended March 31, 2026. "We delivered a strong first quarter, with

    4/29/26 7:00:00 AM ET
    $IEX
    Fluid Controls
    Industrials

    Mott Corp. to Offer deltaVision Valve Solutions for Advanced Spacecraft Propulsion Flow Control Systems

    FARMINGTON, Conn. and MUNICH, April 17, 2026 /PRNewswire/ -- Mott Corporation will now offer deltaVision's high‑performance valve and fluid control solutions to North American spacecraft manufacturers, expanding access to propulsion feed‑system components engineered for reliability, cleanliness, and mission assurance. Delivered through a formal partnership with deltaVision, the offering provides customers with significantly shorter lead times for mission‑critical propulsion components. By combining deltaVision's precision valve technology with Mott's propulsion‑grade filtration,

    4/17/26 12:56:00 PM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Ashleman Eric D exercised 15,385 shares at a strike of $93.27 and sold $3,311,195 worth of shares (15,385 units at $215.22) (SEC Form 4)

    4 - IDEX CORP /DE/ (0000832101) (Issuer)

    5/13/26 4:21:49 PM ET
    $IEX
    Fluid Controls
    Industrials

    Director Watts Stanfield Paris was granted 805 shares, increasing direct ownership by 24% to 4,195 units (SEC Form 4)

    4 - IDEX CORP /DE/ (0000832101) (Issuer)

    5/8/26 4:42:34 PM ET
    $IEX
    Fluid Controls
    Industrials

    Director Quiroz Alejandro was granted 805 shares, increasing direct ownership by 25% to 4,030 units (SEC Form 4)

    4 - IDEX CORP /DE/ (0000832101) (Issuer)

    5/8/26 4:41:39 PM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Financials

    Live finance-specific insights

    View All

    IDEX Corporation Declares Regular Quarterly Cash Dividend

    IDEX CORPORATION (NYSE:IEX) today announced that its Board of Directors has approved a regular quarterly cash dividend of $0.73 per common share. This dividend will be paid June 5, 2026 to shareholders of record as of May 22, 2026. This dividend represents the company's 126th consecutive regular quarterly cash dividend payment. About IDEX IDEX Corporation (NYSE:IEX), a global engineered products company, is comprised of three primary business segments – Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety / Diversified Products. Thousands of IDEX employees around the world design and manufacture highly engineered components and applied solutions that are vital

    5/6/26 1:51:00 PM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Reports First Quarter Results

    Highlights (All comparisons are against the prior year period unless otherwise noted) Sales of $887 million increased 9% on a reported basis and 5% organically Reported diluted EPS of $1.61 increased 28% and adjusted diluted EPS of $2.00 increased 14% Record orders of $988 million increased 13% on a reported basis and increased 10% organically Returned capital to shareholders via $76 million of share repurchases and $53 million of dividends Raising full year 2026 organic growth and adjusted EPS guidance ranges   IDEX Corporation (NYSE:IEX) today announced its financial results for the three-month period ended March 31, 2026. "We delivered a strong first quarter, with

    4/29/26 7:00:00 AM ET
    $IEX
    Fluid Controls
    Industrials

    IDEX Corporation to Webcast First Quarter 2026 Earnings Call

    IDEX Corporation (NYSE:IEX) announced today that it will release its first quarter 2026 results on Wednesday, April 29, 2026, prior to market open. An investor conference call and webcast will take place at 8:00 a.m. (CT) that same day with Chief Executive Officer and President Eric Ashleman and Senior Vice President and Chief Financial Officer Sean Gillen. The event and associated earnings presentation will be available via webcast in listen-only mode on the Company's Investor Relations site at https://investors.idexcorp.com. To participate via telephone, please dial 888-596-4144 and use confirmation code 2518354. Telephone participants are asked to connect five minutes prior to the start

    4/2/26 6:01:00 AM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IDEX Corporation

    SC 13G/A - IDEX CORP /DE/ (0000832101) (Subject)

    10/7/24 1:03:55 PM ET
    $IEX
    Fluid Controls
    Industrials

    SEC Form SC 13G/A filed by IDEX Corporation (Amendment)

    SC 13G/A - IDEX CORP /DE/ (0000832101) (Subject)

    2/13/24 5:06:23 PM ET
    $IEX
    Fluid Controls
    Industrials

    SEC Form SC 13G/A filed by IDEX Corporation (Amendment)

    SC 13G/A - IDEX CORP /DE/ (0000832101) (Subject)

    2/12/24 10:07:40 AM ET
    $IEX
    Fluid Controls
    Industrials

    $IEX
    Leadership Updates

    Live Leadership Updates

    View All

    IDEX Corporation Appoints Sean Gillen as SVP, Chief Financial Officer

    IDEX Corporation (NYSE:IEX) today announced the appointment of Sean M. Gillen as Senior Vice President and Chief Financial Officer of the Company, effective January 5, 2026. Akhil Mahendra, who has served as the Company's interim Chief Financial Officer since May 2025, will return to his role as Vice President, Corporate Development. Mr. Gillen brings extensive experience driving financial performance, portfolio discipline, operational efficiency, and strategic growth at large diverse global industrial and manufacturing businesses. He joins IDEX after serving for nearly seven years as Chief Financial Officer of AAR CORP. (NYSE:AIR), a provider of aviation services to the aerospace and defe

    12/4/25 4:47:00 PM ET
    $AIR
    $IEX
    Aerospace
    Industrials
    Fluid Controls

    Littelfuse Names Abhi Khandelwal Chief Financial Officer

    Littelfuse, Inc. (NASDAQ:LFUS), a leader in developing smart solutions that enable safe and efficient electrical energy transfer, today announced that Abhi Khandelwal has been appointed Executive Vice President and Chief Financial Officer, effective June 18, 2025. Mr. Khandelwal brings more than 20 years of financial and operational experience to Littelfuse, most recently serving as Executive Vice President and Chief Financial Officer at IDEX Corporation (NYSE:IEX). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527700889/en/Abhi Khandelwal, Chief Financial Officer Dr. Greg Henderson, Littelfuse President & Chief Executive Of

    5/27/25 7:00:00 AM ET
    $IEX
    $LFUS
    $CIR
    Fluid Controls
    Industrials
    Electrical Products
    Energy

    IDEX Corporation Appoints Stephanie Disher and Matthijs Glastra to Board of Directors; David Parry and Livingston Satterthwaite to Retire

    IDEX Corporation (NYSE:IEX) today announced the appointment of Stephanie ("Steph") Disher and Matthijs Glastra to the company's Board of Directors. The appointments, effective Friday, February 21, 2025, increase the size of the Board from 10 to 12 directors. Ms. Disher will serve on the Board's Nominating and Corporate Governance Committee, and Mr. Glastra will serve on the Board's Audit Committee. Ms. Disher currently serves as Chief Executive Officer of Atmus Filtration Technologies Inc. (NYSE:ATMU), a leader in filtration and media solutions. She has extensive global leadership experience in finance and operations from her time at Atmus, Cummins Inc. and BP, p.l.c. Mr. Glastra currentl

    2/20/25 5:07:00 PM ET
    $ATMU
    $IEX
    $NOVT
    Auto Parts:O.E.M.
    Consumer Discretionary
    Fluid Controls
    Industrials